Team:NCTU Formosa/Safe Lab Work

Safe Lab work

Researcher Safety in Everyday lab

Each undergraduate experiment is completed in the synthetic biology labs of Department of Biotechnology in National Chiao Tung University. The labs strictly follow all the institutional, local, and federal regulations. Prior to working in the standard level 1 facilities, all members are required to attend mandatory experimental and laboratory safety training, which provides a general understanding of primary and secondary barriers in the lab. All access of non-members is restricted by the usage of IC card. The laboratory head of biosafety is BoBo (balderdash034@gmail.com).

Researcher Safety in Everyday lab

Each undergraduate experiment is completed in the synthetic biology labs of Department of Biotechnology in National Chiao Tung University. The labs strictly follow all the institutional, local, and federal regulations. Prior to working in the standard level 1 facilities, all members are required to attend mandatory experimental and laboratory safety training, which provides a general understanding of primary and secondary barriers in the lab. All access of non-members is restricted by the usage of IC card. The laboratory head of biosafety is BoBo (balderdash034@gmail.com).

Reference
 [1] Applications of single-chain variable fragment antibodies in therapeutics and diagnostics, Nina E. Weisser 1, J. Christopher Hall (2009)
[2] Stability Engineering of Antibody Single-chain Fv Fragments, Arne WoÈ rn and Andreas PluÈ ckthun (2001)
[3] From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. 1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School (2008)
[4] From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. 1Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School (2008)
[5] Molecular-targeted agents combination therapy for cancer: Developments and potentials Feifei Li1,2,3, Changqi Zhao1,2 and Lili Wang3 Beijing Normal University, Beijing, China (2013)
[6] In vitro Companion Diagnostics Device, Guidance for Industry and Food and Drug Administration Staff document issued on: August 6, 2014
[7] Evolutionary dynamics of cancer in response to targeted combination therapy Ivana Bozic, Johannes G Reiter, Benjamin Allen, Tibor Antal, Krishnendu Chatterjee,Preya Shah, Yo Sup Moon, Amin Yaqubie, Nicole Kelly, Dung T Le, Evan J Lipson, Paul BChapman, Luis A Diaz Jr, Bert Vogelstein, Martin A Nowak (2013)
[8] https://www.patientresource.com/Personalized_Treatment_Targeted_Therapy.aspx


Back to project


Go to Design